Search Results - scleroderma%2c+systemic

2 Results Sort By:
New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications
SMAD7 conditional knockout mice are available for licensing. SMAD7 can be knocked out by breeding with CRE-recombinase transgenic mice with a variety of promoters to yield tissue or cell type-specific deletions of SMAD7. SMAD7 has been shown to play a role in bone morphogenesis, cardiovascular tissue generation, immune regulation and fibrosis. Therefore,...
Published: 10/28/2024   |   Inventor(s): Marilyn Diaz
Keywords(s): BAXXXX, Chromosome 7, monosomy, Conditional, Deletion, Deletion 7, Gene., Mouse, RXXXXX, Scleroderma, Scleroderma, systemic, SMAD7, Strain
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Research Materials, ResearchProducts > Animal Models
Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21
This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of...
Published: 10/28/2024   |   Inventor(s): Thomas Wynn
Keywords(s): Asbestosis, CB1AXX, CB1XXX, CB6XXX, CBXXXX, CXXXXX, Cystic fibrosis, DEFICIENCY, FIBROSIS, Hepatitis A, Hepatitis D, Hepatitis E, IL-21, Immunity, Inflammmation, Patent Category - Biotechnology, RECEPTOR, REDUCES, SCHISTOSOMIASIS, Schistosomiasis (Schistosoma sp.), Scleroderma, Scleroderma, systemic, Tissue, TYPE-2
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics